Identification of a gene on human chromosome 8q11 that is differentially expressed during prostate-cancer progression

Author(s):  
Glenn T.G. Chang ◽  
Nita Tapsi ◽  
Martine Steenbeek ◽  
Leen J. Blok ◽  
Wytske M. van Weerden ◽  
...  
2014 ◽  
Vol 395 (9) ◽  
pp. 991-1001 ◽  
Author(s):  
Sara Samaan ◽  
Zsuzsanna Lichner ◽  
Qiang Ding ◽  
Carol Saleh ◽  
Joseph Samuel ◽  
...  

Abstract MicroRNAs (miRNAs) are short RNA nucleotides that negatively regulate their target genes. They are differentially expressed in prostate cancer. Kallikreins are genes that encode serine proteases and are dysregulated in cancer. We elucidated a miRNA-kallikrein network that can be involved in prostate cancer progression. Target prediction identified 23 miRNAs that are dysregulated between high and low risk biochemical failure and are predicted to target five kallikreins linked to prostate cancer; KLK2, KLK3, KLK4, KLK14 and KLK15. We also identified 14 miRNAs that are differentially expressed between Gleason grades and are predicted to target these kallikreins. This demonstrates that kallikreins are downstream effectors through which miRNAs influence tumor progression. We show, through in-silico and experimental analysis, that miR-378/422a and its gene targets PIK3CG, GRB2, AKT3, KLK4 and KLK14 form an integrated circuit in prostate cancer. Our analysis shows that a minisatellite sequence in the kallikrein locus consists of a number of microsatellite repeats that represent predicted miRNA response elements. A number of kallikrein and non-kallikrein prostate cancer-related genes share these microsatellite repeats. We validated some of these interactions in prostate cancer cell lines. Finally, we provide preliminary evidence on the presence of a miRNA-mediated cross-talk between kallikreins, including a kallikrein pseudogene.


2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Nicholas Erho ◽  
Christine Buerki ◽  
Timothy J. Triche ◽  
Elai Davicioni ◽  
Ismael A. Vergara

Prostate cancer is a clinically and biologically heterogeneous disease. Deregulation of splice variants has been shown to contribute significantly to this complexity. High-throughput technologies such as oligonucleotide microarrays allow for the detection of transcripts that play a role in disease progression in a transcriptome-wide level. In this study, we use a publicly available dataset of normal adjacent, primary tumor, and metastatic prostate cancer samples (GSE21034) to detect differentially expressed coding and non-coding transcripts between these disease states. To achieve this, we focus on transcript-specific probe selection regions, that is, those probe sets that correspond unambiguously to a single transcript. Based on this, we are able to pinpoint at the transcript-specific level transcripts that are differentially expressed throughout prostate cancer progression. We confirm previously reported cases and find novel transcripts for which no prior implication in prostate cancer progression has been made. Furthermore, we show that transcript-specific differential expression has unique prognostic potential and provides a clinically significant source of biomarker signatures for prostate cancer risk stratification. The results presented here serve as a catalog of differentially expressed transcript-specific markers throughout prostate cancer progression that can be used as basis for further development and translation into the clinic.


2005 ◽  
Vol 173 (4S) ◽  
pp. 126-127
Author(s):  
Yingming Li ◽  
Melissa Thompson ◽  
Zhu Chen ◽  
Bahaa S. Malaeb ◽  
David Corey ◽  
...  

2006 ◽  
Vol 175 (4S) ◽  
pp. 155-156
Author(s):  
Matthias D. Hofer ◽  
Sven Perner ◽  
Haojie Li ◽  
Rainer Kuefer ◽  
Richard E. Hautmann ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document